A Phase III, randomized, double-blind, multicenter study of adjuvant nivolumab vs placebo in patients (pts) with high-risk invasive urothelial carcinoma (UC; CheckMate 274) Meeting Abstract
| Authors: | Bajorin, D.; Galsky, M. D.; Gschwend, J. E.; Tomita, Y.; Azrilevich, A.; Witjes, F. |
| Abstract Title: | A Phase III, randomized, double-blind, multicenter study of adjuvant nivolumab vs placebo in patients (pts) with high-risk invasive urothelial carcinoma (UC; CheckMate 274) |
| Meeting Title: | 42nd ESMO Congress (ESMO 2017) |
| Journal Title: | Annals of Oncology |
| Volume: | 28 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2017 Sep 8-12 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2017-09-01 |
| Start Page: | mdx371.075 |
| Language: | English |
| ACCESSION: | WOS:000411324002111 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdx371.075 |
| Notes: | Meeting Abstract: 921TiP -- Appears on page 327 of the abstract book -- Source: Wos |
